AR089812A1 - Agente terapeutico para la diabetes mellitus - Google Patents
Agente terapeutico para la diabetes mellitusInfo
- Publication number
- AR089812A1 AR089812A1 ARP130100233A ARP130100233A AR089812A1 AR 089812 A1 AR089812 A1 AR 089812A1 AR P130100233 A ARP130100233 A AR P130100233A AR P130100233 A ARP130100233 A AR P130100233A AR 089812 A1 AR089812 A1 AR 089812A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- therapeutic agent
- formula
- mellitus diabetes
- therapeutic
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- -1 2-phenylthiazole compound Chemical class 0.000 abstract 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000004153 glucose metabolism Effects 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012015351 | 2012-01-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR089812A1 true AR089812A1 (es) | 2014-09-17 |
Family
ID=48873581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130100233A AR089812A1 (es) | 2012-01-27 | 2013-01-25 | Agente terapeutico para la diabetes mellitus |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20150005506A1 (Direct) |
| EP (1) | EP2808018B1 (Direct) |
| JP (1) | JP5924699B2 (Direct) |
| KR (1) | KR20140134266A (Direct) |
| CN (1) | CN104066430A (Direct) |
| AR (1) | AR089812A1 (Direct) |
| AU (1) | AU2013212865A1 (Direct) |
| BR (1) | BR112014017902A2 (Direct) |
| CA (1) | CA2862602A1 (Direct) |
| HK (1) | HK1201209A1 (Direct) |
| IN (1) | IN2014DN05972A (Direct) |
| MX (1) | MX2014008484A (Direct) |
| RU (1) | RU2014134845A (Direct) |
| TW (1) | TW201334779A (Direct) |
| WO (1) | WO2013111870A1 (Direct) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104610190B (zh) * | 2015-02-10 | 2016-08-17 | 佛山市赛维斯医药科技有限公司 | 一类含环丙基脒结构的卤代苯基噻唑羧酸酰胺类化合物及用途 |
| CN104628672A (zh) * | 2015-02-10 | 2015-05-20 | 佛山市赛维斯医药科技有限公司 | 一类含苯基脒结构的烷氧苯基噻唑羧酸酰胺类化合物及用途 |
| CN104628673A (zh) * | 2015-02-10 | 2015-05-20 | 佛山市赛维斯医药科技有限公司 | 一类含叔丁基脒结构的腈基苯噻唑羧酸酰胺类化合物及用途 |
| CN104628671B (zh) * | 2015-02-10 | 2016-04-13 | 佛山市赛维斯医药科技有限公司 | 含苯基脒结构的硝基苯噻唑羧酸酰胺类化合物及用途 |
| CN104610188B (zh) * | 2015-02-10 | 2016-07-27 | 佛山市赛维斯医药科技有限公司 | 含苯基脒结构的腈基苯噻唑羧酸酰胺类化合物、其制备及用途 |
| KR102473677B1 (ko) * | 2015-08-17 | 2022-12-02 | 삼성디스플레이 주식회사 | 액정 표시 장치 |
| AR107661A1 (es) | 2016-02-19 | 2018-05-23 | Nat Univ Corp Tottori Univ | Agente terapéutico o profiláctico para la demencia |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122008000051I1 (de) * | 1990-11-30 | 2009-02-05 | Teijin Ltd | 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel |
| HUP9902721A2 (hu) * | 1997-11-25 | 1999-12-28 | The Procter & Gamble Co. | Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület |
| US20050074442A1 (en) * | 2002-03-13 | 2005-04-07 | Natarajan Ranganathan | Compositions and methods for augmenting kidney function |
| WO2006012438A2 (en) * | 2004-07-21 | 2006-02-02 | University Of Florida Research Foundation, Inc. | Compositions and methods for treatment and prevention of insulin resistance |
| CA2617161A1 (en) * | 2005-07-21 | 2007-02-15 | University Of Florida Research Foundation, Inc. | Compositions and methods for treatment and prevention of hyperuricemia related health consequences |
| WO2007019153A2 (en) | 2005-08-03 | 2007-02-15 | Tap Pharmaceutical Products, Inc. | Methods for treating hypertension |
| JP2009516691A (ja) * | 2005-11-21 | 2009-04-23 | タツプ・フアーマシユーテイカル・プロダクツ・インコーポレイテツド | Ｑｔ間隔延長およびこれに伴う疾病の治療 |
| JP2007210978A (ja) * | 2006-02-13 | 2007-08-23 | Hiroshima Univ | 耐糖能障害、ｉｉ型糖尿病、高脂血症、メタボリックシンドローム、内臓脂肪型肥満、脂肪肝または非アルコール性脂肪性肝炎の予防・治療剤 |
| KR20160031040A (ko) | 2006-11-13 | 2016-03-21 | 다케다 파마슈티칼스 유에스에이, 인코포레이티드 | 크산틴 옥시도리덕타아제 억제제를 사용하여 신장 기능을 보존하는 방법 |
| ES2513390T3 (es) * | 2007-11-27 | 2014-10-27 | Ardea Biosciences, Inc. | Nuevos compuestos y composiciones, y métodos de uso |
| EP2266989B1 (en) * | 2008-03-31 | 2015-09-02 | C&c Research Laboratories | Heterocyclic derivatives |
| JP5431457B2 (ja) * | 2008-04-30 | 2014-03-05 | ウェルスタット セラピューティクス コーポレイション | 尿酸を減少させるテトラゾール化合物 |
| CN102105153B (zh) * | 2008-05-22 | 2014-03-05 | 百时美施贵宝公司 | Sglt2抑制剂的医药用途和含该抑制剂的组合物 |
| CN102256488A (zh) * | 2008-10-19 | 2011-11-23 | 理查德·J·约翰逊 | 伴随代谢失衡慢性肾病的治疗组合物和治疗方法 |
| EP2470268A4 (en) * | 2009-08-24 | 2012-12-26 | Wound Man Pty Ltd | PURING-ORIENTED DIAGNOSIS AND THERAPY OF WOUNDS |
| WO2011159745A1 (en) * | 2010-06-16 | 2011-12-22 | Takeda Pharmaceuticals North America, Inc. | Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors |
| SG186798A1 (en) * | 2010-06-25 | 2013-02-28 | Teijin Pharma Ltd | Sustained-release therapeutic agent for hypertension and renal dysfunction |
-
2013
- 2013-01-25 BR BR112014017902A patent/BR112014017902A2/pt not_active IP Right Cessation
- 2013-01-25 KR KR1020147020342A patent/KR20140134266A/ko not_active Withdrawn
- 2013-01-25 TW TW102102886A patent/TW201334779A/zh unknown
- 2013-01-25 AR ARP130100233A patent/AR089812A1/es unknown
- 2013-01-25 IN IN5972DEN2014 patent/IN2014DN05972A/en unknown
- 2013-01-25 CN CN201380006730.6A patent/CN104066430A/zh active Pending
- 2013-01-25 HK HK15101890.2A patent/HK1201209A1/xx unknown
- 2013-01-25 JP JP2013555326A patent/JP5924699B2/ja not_active Expired - Fee Related
- 2013-01-25 AU AU2013212865A patent/AU2013212865A1/en not_active Abandoned
- 2013-01-25 MX MX2014008484A patent/MX2014008484A/es unknown
- 2013-01-25 US US14/372,961 patent/US20150005506A1/en not_active Abandoned
- 2013-01-25 RU RU2014134845A patent/RU2014134845A/ru not_active Application Discontinuation
- 2013-01-25 EP EP13740913.2A patent/EP2808018B1/en not_active Not-in-force
- 2013-01-25 WO PCT/JP2013/051627 patent/WO2013111870A1/ja not_active Ceased
- 2013-01-25 CA CA2862602A patent/CA2862602A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2862602A1 (en) | 2013-08-01 |
| EP2808018A4 (en) | 2015-07-15 |
| IN2014DN05972A (Direct) | 2015-06-26 |
| KR20140134266A (ko) | 2014-11-21 |
| JP5924699B2 (ja) | 2016-05-25 |
| WO2013111870A1 (ja) | 2013-08-01 |
| AU2013212865A1 (en) | 2014-08-14 |
| RU2014134845A (ru) | 2016-03-20 |
| TW201334779A (zh) | 2013-09-01 |
| EP2808018A1 (en) | 2014-12-03 |
| MX2014008484A (es) | 2014-10-14 |
| US20150005506A1 (en) | 2015-01-01 |
| HK1201209A1 (en) | 2015-08-28 |
| BR112014017902A2 (pt) | 2017-08-22 |
| EP2808018B1 (en) | 2018-03-14 |
| CN104066430A (zh) | 2014-09-24 |
| JPWO2013111870A1 (ja) | 2015-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR093093A1 (es) | Tratamientos y profilaxis para el sindrome de lisis tumoral | |
| AR092661A1 (es) | Inhibidor de quinasas reordenadas durante la transfeccion (ret) y un metodo para identificar un paciente sensible a un compuesto representado por la formula (1) | |
| AR089812A1 (es) | Agente terapeutico para la diabetes mellitus | |
| DK2970216T3 (da) | Biarylamidforbindelser som kinaseinhibitorer | |
| MX2020003415A (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso. | |
| EA201690020A1 (ru) | Применение производных пиразолопиридина для лечения рака мочевого пузыря | |
| EA201492023A1 (ru) | Регуляторы пути комплемента и их применение | |
| CR20120448A (es) | Compuesto heterocíclico | |
| EA201690223A1 (ru) | Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение | |
| PH12015502628A1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
| MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
| NZ703989A (en) | Alkoxy pyrazoles as soluble guanylate cyclase activators | |
| UY32816A (es) | Formulación farmacéutica a base de 1-[2-(2,1,3-benzotiadiazol-5-ilamino)-6(2,6-diclorofenil)-pirido[2,3-d] pirimidin-7-il]-3-tert-butil-uréa | |
| DOP2006000170A (es) | Nuevos derivados de espirocromanona | |
| EA201590200A1 (ru) | Модуляторы пути активации комплемента и их применение | |
| MX2015006039A (es) | Derivados de pirimidin-2, 4-diamina para el tratamiento de cancer. | |
| CO6491060A2 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| MX2015002669A (es) | Metodos de administracion de tratamiento con pirfenidona. | |
| PH12014501967B1 (en) | Benzodioxanes in combination with other actives for inhibiting leukotriene production | |
| MX2020005736A (es) | Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida. | |
| CU20150084A7 (es) | Derivados del ácido 4-((1,1) bisfenil -4-il)-3-(3-fosfonopropanamido)butanoico,activo como inhibidores de nep(endopeptidasa neutral) | |
| WO2014107730A3 (en) | Use of fatty acid niacin conjugates for treating diseases | |
| MX2016004847A (es) | Derivados de piperazina y su uso como medicamento. | |
| AR088287A1 (es) | Agente terapeutico y agente preventivo para la enfermedad desmielinizante | |
| DOP2012000056A (es) | Agente terapeutico para trastornos de ansiedad |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |